Mr. Ori Karev Joins Precipio Executive Team As Chief Strategy Officer
April 18 2019 - 8:45AM
Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO)
announced today that Mr. Ori Karev has joined the company as its
Chief Strategy Officer. Ori was formerly CEO of UnitedHealthcare
Global, the International division of United Healthcare, the
world’s largest health insurance provider. Under Ori’s leadership,
UnitedHealthcare Global expanded its operations to more than 100
countries, employing more than 1,000 FTEs. Ori was responsible for
the establishment and management of partnerships in numerous
countries including China, Japan, Korea, England, Portugal, and the
Philippines; and oversaw multiple mergers and acquisitions during
his tenure there.
Ori is a seasoned executive with over 30 years of executive
experience in the healthcare, insurance and mobility industries. An
attorney by training, Ori executed numerous global M&A
transactions earlier in his career working at Ernst & Young,
and at a boutique NY law firm.
Ori will be responsible for working with Precipio’s senior
executive team to develop, as well as execute its expansion
strategy both domestically and globally. In the coming months,
Precipio intends to launch its global initiatives, delivering
the highest quality pathology services to clinicians and patients,
worldwide.
Furthermore, through Ori’s vast professional network, Precipio
will seek to initiate new relationships with various healthcare
organizations worldwide which have been exploring an adoption of
some of Precipio’s technologies, including: IV-Cell, HemeScreen and
ICE-COLD PCR. These efforts are intended to enhance Precipio’s
existing domestic market penetration activities.
Ori will also be working with leading US health payors in order
to identify opportunities where Precipio might be able to deliver
better outcomes at lower costs, by addressing the inherent costly
challenges arising from misdiagnosis, and deploying Precipio’s
successful and proprietarily developed processes and solutions.
“I am proud to have Ori join our executive team. Ori will add to
our leadership team a unique combination of talent, experience,
vision and execution capabilities that will take the company to a
whole new level,” said Ilan Danieli, CEO of Precipio. “In the few
weeks we have been working together, we have already plotted new
initiatives and have made great progress; I am confident the
company will see a substantive impact in the near, and certainly
the long term. I welcome Ori to our team.”
“Precipio is leading with vision, experience and determination
in a field where recognition of value is, more often than not, a
matter of life or death,” said Ori Karev. “I am eager to be part of
this amazing team which is facilitating the globalization of
Precipio’s unique value proposition - superior diagnostic &
interpretive capabilities - to demanding and deserving communities,
worldwide.”
About Precipio
Precipio has built a platform designed to eradicate the problem
of misdiagnosis by harnessing the intellect, expertise and
technology developed within academic institutions and delivering
quality diagnostic information to physicians and their patients
worldwide. Through its collaborations with world-class academic
institutions specializing in cancer research, diagnostics and
treatment such as the Yale School of Medicine and Harvard’s
Dana-Farber Cancer Institute, Precipio offers a new standard of
diagnostic accuracy enabling the highest level of patient care. For
more information, please visit www.precipiodx.com.
Forward-Looking Statements
Certain statements in this press release constitute
“forward-looking statements,” within the meaning of federal
securities laws including financial projections related thereto and
potential market opportunity, plans and prospects and other
statements containing the words “anticipate,” “intend,” “may,”
“plan,” “predict,” “will,” “would,” “could,” “should,” and similar
expressions, constitute forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995.
The Company's actual results could differ materially from those
anticipated in these forward-looking statements as a result of
various factors. Factors that could cause future results to
materially differ from the recent results or those projected in
forward-looking statements include the known risks, uncertainties
and other factors described in the Company’s Annual Report on Form
10-K for the year ended December 31, 2018 as filed on April 16,
2019 as well as the Company’s prior filings and from time to time
in the Company’s subsequent filings with the Securities and
Exchange Commission. Any change in such factors, risks and
uncertainties may cause the actual results, events and performance
to differ materially from those referred to in such statements. All
information in this press release is as of the date of the release
and the Company does not undertake any duty to update this
information, including any forward-looking statements, unless
required by law.
Inquiries:
investors@precipiodx.com
+1-203-787-7888
Precipio (NASDAQ:PRPO)
Historical Stock Chart
From Apr 2024 to May 2024
Precipio (NASDAQ:PRPO)
Historical Stock Chart
From May 2023 to May 2024